A new study by researchers at Ireland's Maynooth University, based on patient data gathered by the US-based Michael J. Fox Foundation, found that an overwhelming 84% of patients with Parkinson's ...

Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.

Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale - MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity ...

Sleep problems are very common in people with Parkinson’s disease and are associated with poorer quality of life in patients, ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

So I really depend on my medication." Sir Peter Luff, a former defence minister and MP for Mid Worcestershire, explained how ...

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

Kevin Hill, 65, used to suffer sleepless nights due to his harrowing Parkinson's disease symptoms. Now, he forgets about his ...

A few years after Patrick Morrissey, 53, learned he had early onset Parkinson's disease, a group of friends came to him with ...

Scientists from the Institute of Nano Science and Technology (INST) Mohali, an autonomous institute of the Department of ...